Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bladder Control Clear all
Completed Phase 4 Interventional Results available

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

NCT01302067
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine 8mg, Fesoterodine 4mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 130 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Jul 23, 2026, 6:22 PM EDT
Active, not recruiting Phase 3 Interventional

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

NCT03104517
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
AMDC-USR (iltamiocel), Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

NCT00919113
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
2% sodium chondroitin sulfate, Placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Boulder, Colorado • Denver, Colorado • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jul 23, 2026, 6:22 PM EDT
Enrolling by invitation Not applicable Interventional

HIFEM Technology for Post-Radical Prostatectomy and Post-Holmium Laser Prostate Surgery

NCT06803602
View directory record Official record
Conditions
Holmium Laser Prostate Surgery, Radical Prostatectomy
Interventions
EMSELLA®, Sham Comparator Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 23, 2026, 6:22 PM EDT
Not listed Phase 4 Interventional

Oral vs Intravesical Analgesia for Office Bladder Botox Injections

NCT03755089
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Detrusor Instability
Interventions
Phenazopyridine, Lidocaine 2% Injectable Solution
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Jul 23, 2026, 6:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of Bladder Flap vs.None

NCT00470288
View directory record Official record
Conditions
Cesarean Delivery Procedures
Interventions
bladder flap during cesarean section
Procedure
Lead sponsor
Mountain Area Health Organization Center
Other
Eligibility
Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 23, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

NCT07225205
View directory record Official record
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Jul 23, 2026, 6:22 PM EDT
Not listed Phase 4 Interventional

Gentamicin Bladder Instillation Trial

NCT01884467
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin Succinate Suspension, Placebo, Urotherapy
Drug · Behavioral
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 23, 2026, 6:22 PM EDT
Terminated Phase 4 Interventional

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

NCT01092624
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Drug · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

NCT00507455
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions
solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

NCT00666562
View directory record Official record
Conditions
Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
Interventions
Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
Dietary Supplement · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 23, 2026, 6:22 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Interventions
CTX-009, Paclitaxel
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 6:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy

NCT01171027
View directory record Official record
Conditions
Gall Bladder Diseases
Interventions
NOTES Cholecystectomy, Laparoscopic Cholecystectomy
Procedure
Lead sponsor
Natural Orifice Surgery Consortium for Assessment and Research
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Jul 23, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retropubic Hydrodissection and Trocar-induced Bladder Perforation During Retropubic Midurethral Slings

NCT07208682
View directory record Official record
Conditions
Bladder Perforation, Retropubic Midurethral Sling, Retropubic Hydrodissection
Interventions
retropubic hydrodissection
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 23, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional

Add-On ZIDA Sock Therapy for Overactive Bladder

NCT07432659
View directory record Official record
Conditions
Overactive Bladder
Interventions
ZIDA Control Sock
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional

A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers

NCT02750280
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcer
Interventions
MatriStem® [Urinary Bladder Matrix (UBM)], Mepilex® [Silicone foam dressing]
Device
Lead sponsor
Calvary Hospital, Bronx, NY
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 2 Interventional

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

NCT00088946
View directory record Official record
Conditions
Bladder Cancer
Interventions
Polyphenon E, erlotinib hydrochloride, Erlotinib placebo, Polyphenon E
Dietary Supplement · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 23, 2026, 6:22 PM EDT
Completed Phase 2 Interventional

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

NCT01294982
View directory record Official record
Conditions
Overactive Bladder
Interventions
AOBO-001, Placebo
Drug
Lead sponsor
American Oriental Bioengineering, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 23, 2026, 6:22 PM EDT